Syntekabio签署抗癌化合物发现合同——瞄准6万亿AI新药开发市场

[PharmNews] Syntekabio is tightening its grip on the AI 药物开发 market, projected to grow to KRW 6 trillion annually by 2027.

Syntekabio (226330, CEO Jongsun Jeong), an AI-based 药物开发 company, announced that it has signed a KRW 400 million 药物开发 contract with RudaCure (CEO Yongho Kim), a company specializing in 感觉障碍 treatment development. The two companies plan to develop new anticancer substances by May 31, 2026.

This contract follows the recent 候选药物 discovery agreement with a NASDAQ-listed company in 美国 last November, marking consecutive achievements.

Syntekabio assesses that these two contracts have laid the foundation for securing KRW 3 billion in revenue next year. This is significant as KOSDAQ-listed companies with annual revenue below KRW 3 billion may face administrative issues.

An industry insider stated, "Syntekabio's consecutive contract achievements are evidence that the AI 药物开发 market is entering full-scale growth. Through collaboration with companies like RudaCure, AI 新药开发 is expected to generate practical outcomes."

팜뉴스

프라임경제